Project Grant R21AI193274
Award Date
6/17/25
Completion Date
5/31/27
Dollars Obligated
$454K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,283 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, effective August 16, 2024 through July 31, 2029, will support research to investigate the effects of targeting immune activation and intestinal barrier on comorbidities in people living with HIV. The research aims to advance...
This Project Grant award under the Allergy and Infectious Diseases Research program (CFDA 93.855) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), in the amount of $800,005.00, with an award date of Nov 21, 2024 and an ultimate completion date of Oct 31, 2029. The grant aims to leverage advancements in biophysics and structural biology to discern how genetic variants in...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) totaling $831,755 supports research to investigate the role of lung-resident macrophage subsets, particularly nerve- and airway-associated macrophages (NAMs), in regulating type 2 immune responses and tissue homeostasis. The research aims to elucidate the mechanisms by which these macrophage populations mediate protective...
This Cooperative Agreement, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support comprehensive research on mapping airway epithelial cell-immune cell interactions in lung diseases like asthma and COPD. The primary awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will receive $798,062 over the 5-year project period from September 2024 to August 2029. The research...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $917,375 to Brigham & Women's Hospital Inc. to conduct research on defining the heterogeneous effector function of human mast cell subsets. The research aims to comprehensively characterize the cytokine, chemokine, and growth factor production profiles of in vitro-derived mast cell subtypes (MCT and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $147,656 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to St. Jude Children's Research Hospital Inc. The grant supports research to determine: 1) the specificity underlying mucin-mediated autolysis inhibition in Streptococcus pneumoniae; 2) the impact of mucin-mediated autolysis inhibition on pneumococcal cytotoxicity; and 3) the genetic determinants required for prolonged...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $637,729 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to President and Fellows of Harvard College (Harvard Medical School) to investigate the molecular mechanisms underlying the activation and regulation of essential bacterial cell wall synthase enzymes. The research aims to develop a detailed mechanistic understanding of these enzymes, which are critical for bacterial growth and potential...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), totaling $578,093, will support research to elucidate the structure and function of a novel damage-associated molecular pattern (DAMP) receptor, CLEC17A, in humans, and its murine counterpart CD209F/G, as well as their common DAMP ligand, GAPDH. The research aims to establish this novel DAMP-DAMP receptor system, understand its...
This Project Grant award, valued at $194,740, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research to characterize the development of lung-resident, self-antigen-specific regulatory T cells (Tregs) following acute lung injury, with the goal of understanding how these "experienced" Tregs can promote tolerance and prevent future lung disease. The...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...